2023
Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited States
2022
Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021
Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, Salomon JA, Menzies NA. Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021. Clinical Infectious Diseases 2022, 76: e350-e359. PMID: 35717642, PMCID: PMC9214178, DOI: 10.1093/cid/ciac438.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionSARS-CoV-2Immunological exposureOmicron variantSevere diseaseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionFuture SARS-CoV-2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsUS populationSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) vaccinationCoronavirus 2 infectionPopulation-level immunityPrior immunological exposurePopulation immunityImmune escapeVaccination dataInfectionInfection statusVaccinationUS statesEffective protectionDiseaseImmunity
2011
Epidemiologic Inference From the Distribution of Tuberculosis Cases in Households in Lima, Peru
Brooks-Pollock E, Becerra MC, Goldstein E, Cohen T, Murray MB. Epidemiologic Inference From the Distribution of Tuberculosis Cases in Households in Lima, Peru. The Journal Of Infectious Diseases 2011, 203: 1582-1589. PMID: 21592987, PMCID: PMC3096792, DOI: 10.1093/infdis/jir162.Peer-Reviewed Original ResearchConceptsHousehold contactsCommunity transmissionHousehold casesPrevious TB infectionNew TB casesHigh-incidence settingsHousehold risk factorsClustering of casesDistribution of casesMajority of casesRisk of diseaseTB infectionActive tuberculosisTB casesCase patientsProtective immunityTuberculosis casesHousehold transmissionRisk factorsNumber of casesHousehold exposureNatural historyTuberculosisCross-sectional dataImmunity